Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development

References

• Antibody therapeutics approved or in regulatory review in the EU or US. Source: Janice M. Reichert, PhD. Antibody Society. 2021. https://www.antibodysociety.org/resources/approved-antibodies
   Google Scholar
• European Pharmacopoeia Monograph 2.6.34.Host-cell protein assays (04/2017:20634).
   Google Scholar
• U.S. Pharmacopeia <1132> Residual host cell protein measurement in biopharmaceuticals. USP39-NF34, 2016.
   Google Scholar
• Points to consider in the manufacture and testing of monoclonal antibody products for human use. In: FDA, ed. FDA-1994-D-0318. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/points-consider-manufacture-and-testing-monoclonal-antibody-products-human-use, 1997.
   Google Scholar
• DNA and host cell protein impurities, routine testing versus validation studies. In: EMA, ed. CPMP/BWP/382/97. www.ema.europa.eu/en/dna-host-cell-protein-impurities-routine-testing-versus-validation-studies, 1997.
   Google Scholar
• Guidance for Industry Q6B Specifications: test procedures and acceptance criteria for biotechnological/biological products. In: ICH, ed. ICH Q6B. www.ich.org/page/quality-guidelines, 1999.
   Google Scholar
• Bee JS, Tie L, Johnson D, Dimitrova MN, Jusino KC, Afdahl CD. Trace levels of the CHO host cell protease cathepsin D caused particle formation in a monoclonal antibody product. Biotechnol Prog. 2015;31(5):1360–13. doi:10.1002/btpr.2150.
   PubMed Web of Science ®Google Scholar
• Luo H, Tie L, Cao M, Hunter AK, Pabst TM, Du J, Field R, Li Y, Wang WK. Cathepsin L causes proteolytic cleavage of Chinese-Hamster-ovary cell expressed proteins during processing and storage: identification, characterization, and mitigation. Biotechnol Prog. 2019;35(1):e2732. doi:10.1002/btpr.2732.
   PubMed Web of Science ®Google Scholar
• Robert F, Bierau H, Rossi M, Agugiaro D, Soranzo T, Broly H, Mitchell-Logean C. Degradation of an Fc-fusion recombinant protein by host cell proteases: identification of a CHO cathepsin D protease. Biotechnol Bioeng. 2009;104(6):1132–41. doi:10.1002/bit.22494.
   PubMed Web of Science ®Google Scholar
• Zhang S, Xiao H, Molden R, Qiu H, Li N. Rapid Polysorbate 80 degradation by liver carboxylesterase in a monoclonal antibody formulated drug substance at early stage development. J Pharm Sci. 2020;109(11):3300–07. doi:10.1016/j.xphs.2020.07.018.
   PubMed Web of Science ®Google Scholar
• Vanderlaan M, Zhu-Shimoni J, Lin S, Gunawan F, Waerner T, Van Cott KE. Experience with host cell protein impurities in biopharmaceuticals. Biotechnol Prog. 2018;34(4):828–37. doi:10.1002/btpr.2640.
   PubMed Web of Science ®Google Scholar
• Rane SS, Dearman RJ, Kimber I, Uddin S, Bishop S, Shah M, Podmore A, Pluen A, Derrick JP. Impact of a heat shock protein impurity on the Immunogenicity of biotherapeutic monoclonal antibodies. Pharm Res. 2019;36(4):51. doi:10.1007/s11095-019-2586-7.
   PubMed Web of Science ®Google Scholar
• Jones M, Palakal N, Wang F, Gaza-Bulesco G, Hurkmans K, Zhao Y, Chitikila C, Clavier S, Liu S, Menesale E, et al. “High-risk” Host Cell Proteins (HCPs): a multi-company collaborative view. Biotechnol Bioeng 2021;118:2870–2885. doi: 10.1002/bit.27808.
   Web of Science ®Google Scholar
• Valente KN, Levy NE, Lee KH, Lenhoff AM. Applications of proteomic methods for CHO host cell protein characterization in biopharmaceutical manufacturing. Curr Opin Biotechnol. 2018;53:144–50. doi:10.1016/j.copbio.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Chen IH, Xiao H, Li N. Improved host cell protein analysis in monoclonal antibody products through ProteoMiner. Anal Biochem. 2020;610:113972. doi:10.1016/j.ab.2020.113972.
   PubMed Web of Science ®Google Scholar
• Chen IH, Xiao H, Daly T, Li N. Improved host cell protein analysis in monoclonal antibody products through molecular weight cutoff enrichment. Anal Chem. 2020;92(5):3751–57. doi:10.1021/acs.analchem.9b05081.
   PubMed Web of Science ®Google Scholar
• Husson G, Delangle A, O’Hara J, Cianferani S, Gervais A, Van Dorsselaer A, Bracewell D, Carapito C. Dual data-independent acquisition approach combining global HCP profiling and absolute quantification of key impurities during bioprocess development. Anal Chem. 2018;90(2):1241–47. doi:10.1021/acs.analchem.7b03965.
   PubMed Web of Science ®Google Scholar
• Abiri N, Pang J, Ou J, Shi B, Wang X, Zhang S, Sun Y, Yang D, Wang Z. Assessment of the immunogenicity of residual host cell protein impurities of OsrHSA. PLoS One. 2018;13(3):e0193339. doi:10.1371/journal.pone.0193339.
   PubMed Web of Science ®Google Scholar
• Bailey-Kellogg C, Gutierrez AH, Moise L, Terry F, Martin WD, De Groot AS. CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production. Biotechnol Bioeng. 2014;111(11):2170–82. doi:10.1002/bit.25286.
   PubMed Web of Science ®Google Scholar
• Jawa V, Joubert MK, Zhang Q, Deshpande M, Hapuarachchi S, Hall MP, Flynn GC. Evaluating Immunogenicity risk due to host cell protein impurities in antibody-based biotherapeutics. AAPS J. 2016;18(6):1439–52. doi:10.1208/s12248-016-9948-4.
   PubMed Web of Science ®Google Scholar
• de Zafra CL, Quarmby V, Francissen K, Vanderlaan M, Zhu-Shimoni J. Host cell proteins in biotechnology-derived products: a risk assessment framework. Biotechnol Bioeng. 2015;112(11):2284–91. doi:10.1002/bit.25647.
   PubMed Web of Science ®Google Scholar
• Huang L, Wang N, Mitchell CE, Brownlee T, Maple SR, De Felippis MR, Novel Sample A. A novel sample preparation for shotgun proteomics characterization of HCPs in antibodies. Anal Chem. 2017;89(10):5436–44. doi:10.1021/acs.analchem.7b00304.
   PubMed Web of Science ®Google Scholar
• Pythoud N, Bons J, Mijola G, Beck A, Cianferani S, Carapito C. Optimized sample preparation and data processing of data-independent acquisition methods for the robust quantification of trace-level host cell protein impurities in antibody drug products. J Proteome Res. 2021, 20, 1, 923–931. DOI: 10.1021/acs.jproteome.0c00664.
   Web of Science ®Google Scholar
• Kufer R, Haindl M, Wegele H, Wohlrab S. Evaluation of peptide fractionation and native digestion as two novel sample preparation workflows to improve HCP characterization by LC–MS/MS. Anal Chem. 2019;91(15):9716–23. doi:10.1021/acs.analchem.9b01259.
   PubMed Web of Science ®Google Scholar
• Clavier S, Fougeron D, Petrovic S, Elmaleh H, Fourneaux C, Bugnazet D, Duffieux F, Masiero A, Mitra-Kaushik S, Genet B, et al. Improving the analytical toolbox to investigate copurifying host cell proteins presence: n-(4)-(β-acetylglucosaminyl)-l-asparaginase case study. Biotechnol Bioeng. 2020;117(11):3368–78. doi:10.1002/bit.27514.
   PubMed Web of Science ®Google Scholar
• Ma J, Kilby GW. Sensitive, rapid, robust, and reproducible workflow for host cell protein profiling in biopharmaceutical process development. J Proteome Res. 2020;19(8):3396–404. doi:10.1021/acs.jproteome.0c00252.
   PubMed Web of Science ®Google Scholar
• Pengelley S, Tremintin G, Evers W, Takanami Y, Liu X, Suckau D, Greig M. In depth analysis of host cell proteins from antibody preparations using PASEF. Bruker Application Note. 2018;LCMS–143.
   Google Scholar
• Doneanu CE, Anderson M, Williams BJ, Lauber MA, Chakraborty A, Chen W. Enhanced detection of low-abundance host cell protein impurities in high-purity monoclonal antibodies down to 1 ppm using ion mobility mass spectrometry coupled with multidimensional liquid chromatography. Anal Chem. 2015;87(20):10283–91. doi:10.1021/acs.analchem.5b02103.
   PubMed Web of Science ®Google Scholar
• Johnson RO, Greer T, Cejkov M, Zheng X, Li N. Combination of FAIMS, Protein A depletion, and native digest conditions enables deep proteomic profiling of host cell proteins in monoclonal antibodies. Anal Chem. 2020;92(15):10478–84. doi:10.1021/acs.analchem.0c01175.
   PubMed Web of Science ®Google Scholar
• Valente KN, Lenhoff AM, Lee KH. Expression of difficult-to-remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessing. Biotechnol Bioeng. 2015;112(6):1232–42. doi:10.1002/bit.25515.
   PubMed Web of Science ®Google Scholar
• Aboulaich N, Chung WK, Thompson JH, Larkin C, Robbins D, Zhu M. A novel approach to monitor clearance of host cell proteins associated with monoclonal antibodies. Biotechnol Prog. 2014;30(5):1114–24. doi:10.1002/btpr.1948.
   PubMed Web of Science ®Google Scholar
• Esser-Skala W, Segl M, Wohlschlager T, Reisinger V, Holzmann J, Huber CG. Exploring sample preparation and data evaluation strategies for enhanced identification of host cell proteins in drug products of therapeutic antibodies and Fc-fusion proteins. Anal Bioanal Chem. 2020;412(24):6583–93. doi:10.1007/s00216-020-02796-1.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Goetze AM, Cui H, Wylie J, Trimble S, Hewig A, Flynn GC. Comprehensive tracking of host cell proteins during monoclonal antibody purifications using mass spectrometry. MAbs. 2014;6(3):659–70. doi:10.4161/mabs.28120.
   PubMed Web of Science ®Google Scholar
• Ranjan S, Chung WK, Hofele R, Heidbrink Thompson J, Bee J, Zhang L, Robbins D, Cramer SM. Investigation of cathepsin D–mAb interactions using a combined experimental and computational tool set. Biotechnol Bioeng. 2019;116(7):1684–97. doi:10.1002/bit.26968.
   PubMed Web of Science ®Google Scholar
• Bee JS, Machiesky LM, Peng L, Jusino KC, Dickson M, Gill J, Johnson D, Lin HY, Miller K, Heidbrink Thompson J, et al. Identification of an IgG CDR sequence contributing to co-purification of the host cell protease cathepsin D. Biotechnol Prog. 2017;33(1):140–45. doi:10.1002/btpr.2397.
   PubMed Web of Science ®Google Scholar
• Tran B, Grosskopf V, Wang X, Yang J, Walker D Jr., Yu C, McDonald P. Investigating interactions between phospholipase B-Like 2 and antibodies during Protein A chromatography. J Chromatogr A. 2016;1438:31–38. doi:10.1016/j.chroma.2016.01.047.
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;Feb 16;2011(2):CD008794. doi: 10.1002/14651858.CD008794.pub2.
   Web of Science ®Google Scholar
• Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 2014;10(10):612–27. doi:10.1038/nrrheum.2014.123.
   PubMed Web of Science ®Google Scholar
• Sisodiya VN, Lequieu J, Rodriguez M, McDonald P, Lazzareschi KP. Studying host cell protein interactions with monoclonal antibodies using high throughput protein A chromatography. Biotechnol J. 2012;7(10):1233–41. doi:10.1002/biot.201100479.
   PubMed Web of Science ®Google Scholar
• Kornecki M, Mestmacker F, Zobel-Roos S, Heikaus de Figueiredo L, Schluter H, Strube J. Host cell proteins in biologics manufacturing: the good, the bad, and the ugly. Antibodies (Basel). 2017;6 (3):13. doi: 10.3390/antib6030013.
   PubMedGoogle Scholar
• Yuk IH, Nishihara J, Walker D Jr., Huang E, Gunawan F, Subramanian J, Pynn AF, Yu XC, Zhu-Shimoni J, Vanderlaan M, et al. More similar than different: host cell protein production using three null CHO cell lines. Biotechnol Bioeng. 2015;112(10):2068–83. doi:10.1002/bit.25615.
   PubMed Web of Science ®Google Scholar
• Park JH, Jin JH, Ji IJ, An HJ, Kim JW, Lee GM. Proteomic analysis of host cell protein dynamics in the supernatant of Fc-fusion protein-producing CHO DG44 and DUKX-B11 cell lines in batch and fed-batch cultures. Biotechnol Bioeng. 2017;114(10):2267–78. doi:10.1002/bit.26360.
   PubMed Web of Science ®Google Scholar
• Park JH, Jin JH, Lim MS, An HJ, Kim JW, Lee GM. Proteomic analysis of host cell protein dynamics in the culture supernatants of antibody-producing CHO cells. Sci Rep. 2017;7(1):44246. doi:10.1038/srep44246.
   PubMedGoogle Scholar
• Chiu J, Valente KN, Levy NE, Min L, Lenhoff AM, Lee KH. Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations. Biotechnol Bioeng. 2017;114(5):1006–15. doi:10.1002/bit.26237.
   PubMed Web of Science ®Google Scholar
• Nie S, Greer T, O’Brien Johnson R, Zheng X, Torri A, Li N. Simple and sensitive method for deep profiling of host cell proteins in therapeutic antibodies by combining ultra-low trypsin concentration digestion, long chromatographic gradients, and boxcar mass spectrometry acquisition. Anal Chem. 2021;93(10):4383–90. doi:10.1021/acs.analchem.0c03931.
   PubMed Web of Science ®Google Scholar
• Huang Y, Molden R, Hu M, Qiu H, Li N. Toward unbiased identification and comparative quantification of host cell protein impurities by automated iterative LC–MS/MS (HCP-AIMS) for therapeutic protein development. J Pharm Biomed Anal. 2021;200:114069. doi:10.1016/j.jpba.2021.114069.
   PubMed Web of Science ®Google Scholar
• Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics. 2006;5(1):144–56. doi:10.1074/mcp.M500230-MCP200.
   PubMed Web of Science ®Google Scholar
• Claydon A, Widdowson P, Williamson A. Residual host cell protein analysis of NISTmAb: from simplified sample preparation to reliable results. Thermo Scientific Application Note. 2020;73412.
   Google Scholar